King's College London

Research portal

Cholinergic imaging in dementia spectrum disorders

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1376-1386
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number7
Early online date16 Mar 2016
StatePublished - Jun 2016

Bibliographical note

Export Date: 30 July 2016 References: Dementia, W.H.O., (2015) Fact sheet, 362. , Geneva: World Health Organization; Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., Ferri, C.P., The global prevalence of dementia: a systematic review and metaanalysis (2013) Alzheimers Dement, 9, pp. 63-75. , PID: 23305823; Berger-Sweeney, J., The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers (2003) Neurosci Biobehav Rev, 27, pp. 401-411. , COI: 1:CAS:528:DC%2BD3sXms1Oqsbw%3D, PID: 12946692; Schliebs, R., Arendt, T., The cholinergic system in aging and neuronal degeneration (2011) Behav Brain Res, 221, pp. 555-563. , COI: 1:CAS:528:DC%2BC3MXmtFClu7c%3D, PID: 21145918; Pahapill, P.A., Lozano, A.M., The pedunculopontine nucleus and Parkinson’s disease (2000) Brain, 123, pp. 1767-1783. , PID: 10960043; Mesulam, M., Mash, D., Hersh, L., Bothwell, M., Geula, C., Cholinergic innervation of the human striatum, globus pallidus, subthalamic nucleus, substantia nigra, and red nucleus (1992) J Comp Neurol, 323, pp. 252-268. , COI: 1:STN:280:DyaK3s%2FhslWjtA%3D%3D, PID: 1401259; Enna, S.J., Bennett, J.P., Jr., Bylund, D.B., Creese, I., Burt, D.R., Charness, M.E., Neurotransmitter receptor binding: regional distribution in human brain (1977) J Neurochem, 28, pp. 233-236. , COI: 1:CAS:528:DyaE2sXktVaqs7g%3D, PID: 13155; Davies, P., Verth, A.H., Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer’s-type dementia brains (1977) Brain Res, 138, pp. 385-392. , COI: 1:CAS:528:DyaE1cXmtV2htg%3D%3D, PID: 589485; Yamamura, H.I., Kuhar, M.J., Greenberg, D., Snyder, S.H., Muscarinic cholinergic receptor binding: regional distribution in monkey brain (1974) Brain Res, 66, pp. 541-546. , COI: 1:CAS:528:DyaE2cXksVGhsLw%3D; Shimohama, S., Taniguchi, T., Fujiwara, M., Kameyama, M., Biochemical characterization of the nicotinic cholinergic receptors in human brain: binding of (−)[3H]nicotine (1985) J Neurochem, 45, pp. 604-660. , COI: 1:CAS:528:DyaL2MXkvVWlt7w%3D, PID: 2861250; Perry, E.K., Court, J.A., Johnson, M., Piggott, M.A., Perry, R.H., Autoradiographic distribution of [3H]nicotine binding in human cortex: relative abundance in subicular complex (1992) J Chem Neuroanat, 5, pp. 399-405. , COI: 1:CAS:528:DyaK3sXhs1Oqsg%3D%3D, PID: 1418753; Flynn, D.D., Mash, D.C., Characterization of L-[3H]nicotine binding in human cerebral cortex: comparison between Alzheimer’s disease and the normal (1986) J Neurochem, 47, pp. 1948-1954. , COI: 1:CAS:528:DyaL2sXkvVWhtw%3D%3D, PID: 3772387; Bartus, R.T., Dean, R.L., Beer, B., 3rd, Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction (1982) Science, 217, pp. 408-414. , COI: 1:CAS:528:DyaL38XkslShur4%3D, PID: 7046051; Perry, E.K., Gibson, P.H., Blessed, G., Perry, R.H., Tomlinson, B.E., Neurotransmitter enzyme abnormalities in senile dementia: choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue (1977) J Neurol Sci, 34, pp. 247-265. , COI: 1:CAS:528:DyaE1cXkvVKmug%3D%3D, PID: 144789; Davis, K.L., Mohs, R.C., Marin, D., Purohit, D.P., Perl, D.P., Lantz, M., Cholinergic markers in elderly patients with early signs of Alzheimer disease (1999) JAMA, 281, pp. 1401-1406. , COI: 1:STN:280:DyaK1M3jtFCjug%3D%3D, PID: 10217056; Kuhl, D.E., Minoshima, S., Fessler, J.A., Ficaro, E.P., Wieland, D.M., Koeppe, R.A., In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease (1996) Ann Neurol, 40, pp. 399-410; Kuhl, D.E., Koeppe, R.A., Minoshima, S., Snyder, S.E., Ficaro, E.P., Foster, N.L., In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease (1999) Neurology, 52, pp. 691-699; Shinotoh, H., Namba, H., Yamaguchi, M., Fukushi, K., Nagatsuka, S.I., Iyo, M., Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson’s disease and progressive supranuclear palsy (1999) Ann Neurol, 46, pp. 62-69; Bohnen, N.I., Kaufer, D.I., Ivanco, L.S., Lopresti, B., Koeppe, R.A., Davis, J.G., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study (2003) Arch Neurol, 60, pp. 1745-1748; Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B., Davis, J.G., Cognitive correlates of alterations in acetylcholinesterase in Alzheimer’s disease (2005) Neurosci Lett, 380, pp. 127-132; Hilker, R., Thomas, A.V., Klein, J.C., Weisenbach, S., Kalbe, E., Burghaus, L., Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways (2005) Neurology, 65, pp. 1716-1722; Eggers, C., Herholz, K., Kalbe, E., Heiss, W.D., Cortical acetylcholine esterase activity and ApoE4- genotype in Alzheimer disease (2006) Neurosci Lett, 408, pp. 46-50; Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B.J., Constantine, G.M., Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia (2006) J Neurol, 253, pp. 242-247; Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET (2009) Neurology, 73, pp. 273-278; Gilman, S., Koeppe, R.A., Nan, B., Wang, C.N., Wang, X., Junck, L., Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes (2010) Neurology, 74, pp. 1416-1423; Klein, J.C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo (2010) Neurology, 74, pp. 885-892; Hirano, S., Shinotoh, H., Shimada, H., Aotsuka, A., Tanaka, N., Ota, T., Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia (2010) Brain, 133, pp. 2058-2068; Kotagal, V., Müller, M.L.T.M., Kaufer, D.I., Koeppe, R.A., Bohnen, N.I., Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders (2012) Neurosci Lett, 514, pp. 169-172; Mazère, J., Meissner, W.G., Mayo, W., Sibon, I., Lamare, F., Guilloteau, D., Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol (2012) Radiology, 265, pp. 537-543; Asahina, M., Suhara, T., Shinotoh, H., Inoue, O., Suzuki, K., Hattori, T., Brain muscarinic receptors in progressive supranuclear palsy and Parkinson’s disease: a positron emission tomographic study (1998) J Neurol Neurosurg Psychiatry, 65, pp. 155-163; Colloby, S.J., Pakrasi, S., Firbank, M.J., Perry, E.K., Piggott, M.A., Owens, J., In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R)123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia (2006) Neuroimage, 33, pp. 423-429; Kadir, A., Almkvist, O., Wall, A., Långström, B., Nordberg, A., PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease (2006) Psychopharmacology, 188, pp. 509-520; Fujita, M., Ichise, M., Zoghbi, S.S., Liow, J.S., Ghose, S., Vines, D.C., Widespread decrease of nicotinic acetylcholine receptors in Parkinson’s disease (2006) Ann Neurol, 59, pp. 174-177; O’Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., Alpha4beta2 nicotinic receptor status in Alzheimer’s disease using 123I-5IA-85380 single-photon-emission computed tomography (2007) J Neurol Neurosurg Psychiatry, 78, pp. 356-362; Oishi, N., Hashikawa, K., Yoshida, H., Ishizu, K., Ueda, M., Kawashima, H., Quantification of nicotinic acetylcholine receptors in Parkinson’s disease with 123I-5IA SPECT (2007) J Neurol Sci, 256, pp. 52-60; Ellis, J.R., Villemagne, V.L., Nathan, P.J., Mulligan, R.S., Gong, S.J., Chan, J.G., Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: a 2-[18F]fluoro-A-85380 PET study (2008) Neurobiol Learn Mem, 90, pp. 404-412; O’Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations (2008) Neuroimage, 40, pp. 1056-1063; Sabri, O., Kendziorra, K., Wolf, H., Gertz, H.-J., Brust, P., Acetylcholine receptors in dementia and mild cognitive impairment (2008) Eur J Nucl Med Mol Imaging, 35, pp. 30-45; Kas, A., Bottlaender, M., Gallezot, J.D., Vidailhet, M., Villafane, G., Grégoire, M.C., Decrease of nicotinic receptors in the nigrostriatal system in Parkinson’s disease (2009) J Cereb Blood Flow Metab, 29, pp. 1601-1608; Meyer, P.M., Strecker, K., Kendziorra, K., Becker, G., Hesse, S., Woelpl, D., Reduced α4β2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease (2009) Arch Gen Psychiatry, 66, pp. 866-877; Mitsis, E.M., Reech, K.M., Bois, F., Tamagnan, G.D., Macavoy, M.G., Seibyl JP, et al. 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment (2009) J Nucl Med, 50, pp. 1455-1463; Terrière, E., Dempsey, M.F., Herrmann, L.L., Tierney, K.M., Lonie, J.A., O’Carroll RE, et al. 5-(123)I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment (2010) Neurobiol Aging, 31, pp. 1885-1893; Okada, H., Ouchi, Y., Ogawa, M., Futatsubashi, M., Saito, Y., Yoshikawa, E., Alterations in alpha4beta2 nicotinic receptors in cognitive decline in Alzheimer’s aetiopathology (2013) Brain, 136, pp. 3004-3017; Lobo, A., Launer, L.J., Fratiglioni, L., Andersen, K., Di Carlo, A., Breteler, M.M., Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group (2000) Neurology, 54, pp. S4-S9; Dugu, M., Neugroschl, J., Sewell, M., Marin, D., Review of dementia (2003) Mt Sinai J Med, 70, pp. 45-53; Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes (1991) Acta Neuropathol, 82, pp. 239-259; Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L.A., McKeel, D.W., Jr., Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease (2001) Neurology, 56, pp. 127-129; Spires-Jones, T.L., Hyman, B.T., The intersection of amyloid beta and tau at synapses in Alzheimer’s disease (2014) Neuron, 82, pp. 756-771; Davies, P., Maloney, A.J.F., Selective loss of central cholinergic neurons in Alzheimer’s disease (1976) Lancet, 308, p. 1403; Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H., Perry, R.H., Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia (1978) Br Med J, 2, pp. 1457-1459; Coyle, J.T., Price, D.L., DeLong, M.R., Alzheimer’s disease: a disorder of cortical cholinergic innervation (1983) Science, 219, pp. 1184-1190; Bierer, L.M., Haroutunian, V., Gabriel, S., Knott, P.J., Carlin, L.S., Purohit, D.P., Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of the cholinergic deficits (1995) J Neurochem, 64, pp. 749-760; Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., Delon, M.R., Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain (1982) Science, 215, pp. 1237-1239; Irie, T., Fukushi, K., Akimoto, Y., Tamagami, H., Nozaki, T., Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo (1994) Nucl Med Biol, 21, pp. 801-808; Geula, C., Mesulam, M.M., Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer’s disease (1996) Cereb Cortex, 6, pp. 165-177; Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer’s disease (1997) Lancet, 349, pp. 1805-1809; Namba, H., Iyo, M., Shinotoh, H., Nagatsuka, S., Fukushi, K., Irie, T., Preserved acetylcholinesterase activity in aged cerebral cortex (1998) Lancet, 351, pp. 881-882; Koeppe, R.A., Frey, K.A., Snyder, S.E., Meyer, P., Kilbourn, M.R., Kuhl, D.E., Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography trace for measurement of acetylcholinesterase activity in human brain (1999) J Cereb Blood Flow Metab, 19, pp. 1150-1163; Kuhl, D.E., Koeppe, R.A., Fessler, J.A., Minoshima, S., Ackermann, R.J., Carey, J.E., In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM (1994) J Nucl Med, 35, pp. 405-410; Bird, T.D., Stranahan, S., Sumi, S.M., Raskind, M., Alzheimer’s disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups (1983) Ann Neurol, 14, pp. 284-293; Petrou, M., Frey, K.A., Kilbourn, M.R., Scott, P.J., Raffel, D.M., Bohnen, N.I., In vivo imaging of human cholinergic nerve terminals with (-)-5-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses (2014) J Nucl Med, 55, pp. 396-404; Nordberg, A., Hartvig, P., Lilja, A., Viitanen, M., Amberla, K., Lundqvist, H., Decreased uptake and binding of11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography (1990) J Neural Transm Park Dis Dement Sect, 2, pp. 215-224; Nordberg, A., Lundqvist, H., Hartvig, P., Lilja, A., Långström, B., Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains in vivo assessment using positron emission tomography (1995) Alzheimer Dis Assoc Disord, 9, pp. 21-27; Nybäck, H., Halldin, C., Åhlin, A., Curvall, M., Eriksson, L., PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo (1994) Psychopharmacology, 115, pp. 31-36; Nordberg, A., Lundqvist, H., Hartvig, P., Andersson, J., Johansson, M., Hellström-Lindahl, E., Imaging of nicotinic and muscarinic receptors in Alzheimer’s disease: effect of tacrine treatment (1997) Dement Geriatr Cogn Disord, 8, pp. 78-84; Nordberg, A., Winblad, B., Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains (1986) Neurosci Lett, 72, pp. 115-119; Sabbagh, M.N., Shah, F., Reid, R.T., Sue, L., Connor, D.J., Peterson, L.K.N., Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging (2006) Arch Neurol, 63, pp. 1771-1776; Horti, A.G., Villemagne, V.L., The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain (2006) Curr Pharm Des, 12, pp. 3877-3900; Horti, A.G., Gao, Y., Kuwabara, H., Dannals, R.F., Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography (2010) Life Sci, 86, pp. 575-584; Bohnen, N.I., Kaufer, D.I., Hendrickson, R., Ivanco, L.S., Lopresti, B.J., Koeppe, R.A., Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease (2005) J Neurol Neurosurg Psychiatry, 76, pp. 315-319; Kuhl, D.E., Minoshima, S., Frey, K.A., Foster, N.L., Kilbourn, M.R., Koeppe, R.A., Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex (2000) Ann Neurol, 48, pp. 391-395; Shinotoh, H., Aotsuka, A., Fukushi, K., Nagatsuka, S., Tanaka, N., Ota, T., Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET (2001) Neurology, 56, pp. 408-410; Kaasinen, V., Någren, K., Järvenpää, T., Roivainen, A., Yu, M., Oikonen, V., Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer’s disease (2002) J Clin Psychopharmacol, 22, pp. 615-620; Kadir, A., Darreh-Shori, T., Almkvist, O., Wall, A., Grut, M., Strandberg, B., PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD (2008) Neurobiol Aging, 29, pp. 1204-1217; Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E.X., Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease (2001) Biol Psychiatry, 49, pp. 279-288; Marsden, C.D., Basal ganglia disease (1982) Lancet, 320, pp. 1141-1147; Jellinger, K.A., Pathology of Parkinson’s disease (1991) Mol Chem Neuropathol, 14, pp. 153-197; Samii, A., Nutt, J.G., Ransom, B.R., Parkinson’s disease (2004) Lancet, 363, pp. 1783-1793; Whitehouse, P.J., Hedreen, J.C., White, C.L., Price, D.L., Basal forebrain neurons in the dementia of Parkinson disease (1983) Ann Neurol, 13, pp. 243-248; Schrag, A., Psychiatric aspects of Parkinson’s disease (2004) J Neurol, 251, pp. 795-804; Aarsland, D., Andersen, K., Larsen, J.P., Lolk, A., Prevalence and characteristics of dementia in Parkinson disease: an 8-years prospective study (2003) Arch Neurol, 60, pp. 387-392; Hely, M.A., Reid, W.G.J., Adena, M.A., Halliday, G.M., Morris, J.G.L., The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years (2008) Mov Disord, 23, pp. 837-844; Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis (2010) Neurology, 75, pp. 1062-1069; Muslimovic, D., Post, B., Speelman, J.D., Schmand, B., Cognitive profile of patients with newly diagnosed Parkinson disease (2005) Neurology, 65, pp. 1239-1245; McKeith, I.G., Galasko, D., Kosaka, K., Perry, E.K., Dickson, D.W., Hansen, L.A., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop (1996) Neurology, 47, pp. 1113-1124; Whitehouse, P.J., Martino, A.M., Wagster, M.V., Price, D.L., Mayeux, R., Atack, J.R., Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s disease and Parkinson’s disease: an autoradiographic study (1988) Neurology, 38, pp. 720-723; Whitehouse, P.J., Hedreen, J.C., White, C.L., Price, D.L., Basal forebrain neurons in the dementia of Parkinson disease (1983) Ann Neurol, 13, pp. 243-248; Court, J.A., Piggott, M.A., Lloyd, S., Cookson, N., Ballard, C.G., McKeith, I.G., Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication (2000) Neuroscience, 98, pp. 79-87; Graham, A.J., Martin-Ruiz, C.M., Teaktong, T., Ray, M.A., Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders (2002) Curr Drug Targets CNS Neurol Disord, 1, pp. 387-397; Ruberg, M., Rieger, F., Villageois, A., Bonnet, A.M., Agid, Y., Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson’s disease (1986) Brain Res, 362, pp. 83-91; Rinne, J.O., Myllykyla, T., Lo, P., A postmortem study of brain nicotinic receptors in Parkinson’s and Alzheimer’s disease (1991) Brain Res, 547, pp. 155-158; Perry, E.K., Morris, C.M., Court, J.A., Cheng, A., Fairbairn, A.F., McKeith, I.G., Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology (1995) Neuroscience, 64, pp. 385-395; Mendez, M.F., Shapira, J.S., McMurtray, A., Licht, E., Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia (2007) Am J Geriatr Psychiatr, 15, pp. 84-87; Perry, E.K., Irving, D., Kerwin, J.M., McKeith, I.G., Thompson, P., Collerton, D., Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease (1993) Alzheimer Dis Assoc Disord, 7, pp. 69-79; Shiozaki, K., Iseki, E., Uchiyama, H., Watanabe, Y., Haga, T., Kameyama, K., Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease (1999) J Neurol Neurosurg Psychiatry, 67, pp. 209-213; Mulholland, G.K., Kilbourn, M.R., Sherman, P., Carey, J.E., Frey, K.A., Koeppe, R.A., Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist (1995) Nucl Med Biol, 22, pp. 13-17; Otto, C.A., Mulholland, G.K., Perry, S.E., Combs, R., Sherman, P.S., Fisher, S.J., In vitro and ex vivo evaluation of cyclic aminoalkyl benzilates as potential emission tomography ligands for the muscarinic receptor (1989) Nucl Med Biol, 16, pp. 51-55; Koeppe, R.A., Frey, K.A., Zubieta, J.A., Fessler, J.A., Mulholland, G.K., Kilbourn, M.R., Tracer kinetic analysis of [C-11]N-methyl-4-piperidyl benzilate binding to muscarinic cholinergic receptors (1992) J Nucl Med, 33, p. 882; Kloog, Y., Egozi, Y., Sokolovsky, M., Characterization of muscarinic acetylcholine receptors from mouse brain: evidence for regional heterogeneity and isomerization (1979) Mol Pharmacol, 15, pp. 545-558; Lorenz, R., Samnick, S., Dillmann, U., Schiller, M., Ong, M.F., Faßbender, K., Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson’s disease (2014) Acta Neurol Scand, 130, pp. 164-171; Dani, J.A., Bertrand, D., Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system (2007) Annu Rev Pharmacol Toxicol, 47, pp. 699-729. , COI: 1:CAS:528:DC%2BD2sXit1alurk%3D, PID: 17009926; Pimlott, S.L., Piggott, M., Owens, J., Greally, E., Court, J.A., Jaros, E., Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)I]-a-85380 (2004) Neuropsychopharmacology, 29, pp. 108-116. , COI: 1:CAS:528:DC%2BD3sXhtVSqs7bK, PID: 12955099; Buckingham, S.D., Jones, A.K., Brown, L.A., Sattelle, D.B., Nicotinic acetylcholine receptor signaling: roles in Alzheimer’s disease and amyloid neuroprotection (2009) Pharmacol Rev, 61, pp. 39-61. , COI: 1:CAS:528:DC%2BD1MXkvVKjuro%3D, PID: 19293145; Hu, M., Waring, J.F., Gopalakrishnan, M., Li, J., Role of GSK-3beta activation and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in PC12 cells (2008) J Neurochem, 106, pp. 1371-1377. , COI: 1:CAS:528:DC%2BD1cXpsFOisb4%3D, PID: 18485099; Dziewczapolski, G., Glogowski, C.M., Masliah, E., Heinemann, S.F., Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease (2009) J Neurosci, 29, pp. 8805-8815. , COI: 1:CAS:528:DC%2BD1MXovVKgsrw%3D, PID: 19587288; Horti, A.G., Gao, Y., Kuwabara, H., Wang, Y., Abazyan, S., Yasuda, R.P., 18F-ASEM, a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET (2014) J Nucl Med, 55, pp. 672-677. , COI: 1:CAS:528:DC%2BC2cXosVOht7s%3D, PID: 24556591; Wong, D.F., Kuwabara, H., Pomper, M., Holt, D.P., Brasic, J.R., George, N., Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy (2014) Mol Imaging Biol, 16, pp. 730-738. , PID: 25145965


King's Authors


The multifaceted nature of the pathology of dementia spectrum disorders has complicated their management and the development of effective treatments. This is despite the fact that they are far from uncommon, with Alzheimer’s disease (AD) alone affecting 35 million people worldwide. The cholinergic system has been found to be crucially involved in cognitive function, with cholinergic dysfunction playing a pivotal role in the pathophysiology of dementia. The use of molecular imaging such as SPECT and PET for tagging targets within the cholinergic system has shown promise for elucidating key aspects of underlying pathology in dementia spectrum disorders, including AD or parkinsonian dementias. SPECT and PET studies using selective radioligands for cholinergic markers, such as [11C]MP4A and [11C]PMP PET for acetylcholinesterase (AChE), [123I]5IA SPECT for the α4β2 nicotinic acetylcholine receptor and [123I]IBVM SPECT for the vesicular acetylcholine transporter, have been developed in an attempt to clarify those aspects of the diseases that remain unclear. This has led to a variety of findings, such as cortical AChE being significantly reduced in Parkinson’s disease (PD), PD with dementia (PDD) and AD, as well as correlating with certain aspects of cognitive function such as attention and working memory. Thalamic AChE is significantly reduced in progressive supranuclear palsy (PSP) and multiple system atrophy, whilst it is not affected in PD. Some of these findings have brought about suggestions for the improvement of clinical practice, such as the use of a thalamic/cortical AChE ratio to differentiate between PD and PSP, two diseases that could overlap in terms of initial clinical presentation. Here, we review the findings from molecular imaging studies that have investigated the role of the cholinergic system in dementia spectrum disorders.

Download statistics

No data available

View graph of relations

© 2015 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454